Quarterly report pursuant to Section 13 or 15(d)

Corporate Information - Narrative (Details)

v3.21.1
Corporate Information - Narrative (Details) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended
Apr. 24, 2021
Apr. 01, 2021
Mar. 31, 2021
Aug. 31, 2019
Mar. 31, 2021
Mar. 31, 2020
Dec. 31, 2020
May 31, 2013
Business Acquisition [Line Items]                
Cash, cash equivalents and investments     $ 66,800   $ 66,800      
Total revenue         15,633 $ 13,261    
Issuance of common stock, net of issuance costs       $ 50,000 9,673 0    
Net loss         (4,172) (3,597)    
Accumulated deficit     (215,578)   (215,578)   $ (211,406)  
AstraZeneca                
Business Acquisition [Line Items]                
Total revenue     $ 13,000   $ 14,500 $ 2,711    
AstraZeneca | Subsequent Event                
Business Acquisition [Line Items]                
Total revenue   $ 13,000            
AstraZeneca | Private placement | Subsequent Event                
Business Acquisition [Line Items]                
Issuance of common stock, net of issuance costs   $ 10,000            
Boston Pharmaceuticals | Subsequent Event | Exclusive Product License Agreement                
Business Acquisition [Line Items]                
Collaborative arrangement, upfront payment $ 10,000              
Pieris Pharmaceuticals GmbH                
Business Acquisition [Line Items]                
Ownership interest acquired (as a percent)               100.00%